Keep up-to-date with PrECOG by visiting our news page regularly.
Now Open to Enrollment: PrE0404 A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma. NCT03323151
